恩华药业召回重酒石酸卡巴拉汀胶囊，去年销售收入4000万元

Core Viewpoint - The National Medical Products Administration (NMPA) has suspended the import, sale, and use of Sun Pharmaceutical Industries Limited's (Sun Pharma) carbamazepine tartrate capsules, impacting domestic companies like Enhua Pharmaceutical [1][3] Group 1: Recall and Financial Impact - Enhua Pharmaceutical's subsidiary, Enhua Hexin, has initiated a level-three recall of the carbamazepine tartrate capsules it marketed, following the NMPA's announcement [1][3] - The sales revenue from the recalled carbamazepine tartrate capsules was approximately 40 million yuan in 2025, with the recall affecting an estimated sales amount of around 9 million yuan [2][4] - The recall is not expected to significantly impact Enhua Pharmaceutical's overall financial status, as the affected sales amount represents a small proportion of the company's total revenue [4] Group 2: Market Dynamics and Competitors - Carbamazepine tartrate is a first-line drug developed by Novartis for treating mild to moderate Alzheimer's disease, with a high therapeutic index and significant clinical efficacy [5] - Following the suspension of Sun Pharma's product, the market for carbamazepine tartrate capsules in China may be filled by other companies, including Novartis and several domestic firms with approved licenses [6] - The domestic market for carbamazepine tartrate capsules was previously dominated by Novartis, but local companies like Jingxin Pharmaceutical have begun to capture market share, with a reported market size nearing 200 million yuan [6]